HIV Incidence Estimation via PhIP-Seq Multiplexing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serologic assays for estimating HIV incidence are inaccurate due to high variability in the serologic response to HIV infection, particularly in populations with subtype D HIV, and are affected by factors like antiretroviral treatment and CD4 T cell decline, leading to misclassification and unreliable incidence estimates.
Innovation Solution
A method involving a biological sample with antibodies from a subject is mixed with epitopes or peptides from viruses, quantifying antibody binding to estimate cross-sectional incidence or duration of infection, using a phage immunoprecipitation sequencing system (PhIP-Seq) and epitopes derived from a phage library that spans the genomes of multiple viruses, including HIV and EBV, with potential modifications through site-directed mutagenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional serologic assays (BED assay, LAg assay) are used to estimate HIV incidence, then the assay can be performed with existing technology, but the measurement precision is poor due to high variability in serologic response and misclassification in certain populations
Solution Approach 1:
The patent segments the HIV antibody response into multiple independent measurements across 15 different recombinant HIV Env protein targets and 5 gp41 peptide targets. Instead of relying on a single serologic assay measurement, the system divides the assessment into multiple discrete antibody binding measurements, each against a specific viral epitope. This segmentation allows for a more nuanced and accurate characterization of the antibody response, improving incidence estimation precision while maintaining reliability across diverse populations including those with subtype D HIV.
Solution Approach 2:
The patent changes the measurement parameters from traditional single-point serologic assays to a multiplexed array of antibody binding measurements against multiple viral epitopes. By measuring antibody titers and avidity across 20 different HIV protein targets simultaneously, the system transforms the assessment from a single parameter to a multidimensional profile, thereby improving measurement precision and reliability of HIV incidence estimates.
2Measurement precision
If a limited number of antigen targets are used in serologic assays, then the assay complexity is reduced, but the measurement precision deteriorates due to inability to capture the full breadth of antibody response
Solution Approach 1:
The patent creates a universal assay platform that simultaneously measures antibody responses against 20 different HIV viral targets using a single multiplexed immunoassay. This multi-functional system can assess both titer and avidity across diverse HIV subtypes and epitopes in one test, capturing the full breadth of the antibody response. The universal nature of this platform improves measurement precision without requiring multiple separate assays, thereby managing complexity through integration rather than multiplication of test components.
3Measurement precision
If traditional longitudinal cohort methods are used to measure HIV incidence, then the measurement approach is straightforward, but the loss of time is significant due to the need for repeated follow-up over extended periods
Solution Approach 1:
The patent applies preliminary action by using a cross-sectional survey design that identifies recent infections through characteristic antibody patterns at a single time point, rather than requiring longitudinal follow-up. By measuring both titer and avidity across multiple HIV epitopes in a single assay, the system can estimate incidence immediately from prevalence data, capturing the 'leading edge' of the epidemic without the time loss associated with traditional cohort methods. This preliminary assessment of antibody characteristics allows for immediate incidence estimation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate estimation of HIV incidence and duration of infection by identifying novel peptide biomarkers associated with infection stages, enhancing discrimination between early and late-stage infections, and improving the reliability of cross-sectional surveys for HIV/AIDS epidemic surveillance.
Implementation Method 1
mixing the biological sample with two or more epitopes or peptides from the proteins of viruses responsible for the viral infection; quantifying the amount of antibody binding to the epitopes or peptides
Data Source
AI summary
Described are methods for estimating the cross-sectional incidence or duration of infection of a virus. Method steps include obtaining a biological sample with antibodies from a subject having a viral infection. The biological sample is mixed with two or more epitopes or peptides from the proteins of a vims responsible for the viral infection. The amount of antibody binding to the epitopes or peptides is quantified and the cross-sectional incidence or duration of infection of a virus is estimated.